GSK plc (GSK) — research page

US · us-cm-kg/NYSE/GSK · as of 2026-11-08

Identity and listing

The issuer is GSK plc, listed on the NYSE under the ticker GSK, with ISIN US37733W2044 and LEI 5493000HZTVUYLO1D793. Its security type is recorded as non-operating entity type (other). Its segment is not on the record. Its sector is 2834 Pharmaceutical Preparations and its jurisdiction is the United Kingdom. Its listing status is listed, not halted.

The disclosure read

The record holds 301 filings in the window from 2025-11-08 to 2026-11-08, across 164 filing days. The median gap between filing days is 1 day. The latest filing is dated 2026-11-06 and is of type results, 2 days before the record date of 2026-11-08. The NYSE median cadence gap is 6.0 days, the NYSE median latency is 4.0 days, and the NYSE median filings count is 64.0. The sector median cadence gap is 6.0 days, the sector median latency is 4.0 days, and the sector median filings count is 63.0.

window 2025-11-08 to 2026-11-08 · the node's disclosure lines, as get_filings serves them

Auditor

The auditor is not on the record, because the latest annual report cover carries no dei:AuditorName tag, as foreign private issuers and older filings carry none. The auditor's location is not on the record. No auditor changes are on the record.

Events and halts

The lifecycle lines on the record are listings dated 2026-09-15 and 2026-09-22. No delisting and no name change are on the record. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.

Orderability

The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.

rule acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability

Coverage

The record names 14 research houses on the issuer's own investor-relations page: Barclays, Berenberg, BNP Paribas Exane, Citi, Deutsche Bank, Goldman Sachs, Guggenheim Securities, Jefferies, JP Morgan, Morgan Stanley, Redburn, TD Cowen, UBS and Wolfe Research.

Open research

No openly published research notes were found on the record.

Licensed

Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.

As-of depth

The vintage is sealed. Sealed years that hold the issuer are 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.

Sources

9 source pages are named on this page; every value above carries its own source page and read date in the numbers.

10.1

https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)

10.2

https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)

10.3

https://data.sec.gov/submissions/CIK0001131399.json (identity.jurisdiction)

10.4

https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)

10.5

https://mcp.us-cm-kg.ai/events/NYSE/GSK (the disclosure lines)

10.6

https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)

10.7

https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)

10.8

https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus (coverage)

10.9

https://mcp.us-cm-kg.ai/record/NYSE/GSK (the record)

Read it by agent

The same page, signed and receipted: get_research at https://mcp.getissuer.ai/mcp with {"isin":"US37733W2044"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:aa6d549f852c6a62.